IDELVION albutrepenonacog alfa 3500 IU powder (and diluent) for injection

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

Factor IX, Quantity: 3500 IU

Disponible depuis:

CSL Behring Australia Pty Ltd

forme pharmaceutique:

Solution

Composition:

Excipient Ingredients:

Mode d'administration:

Intravenous

Unités en paquet:

3500 IU

Type d'ordonnance:

Not scheduled. Not considered by committee

indications thérapeutiques:

IDELVION is indicated in all patients with haemophilia B for:,? Routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? Control and prevention of bleeding episodes,? Control and prevention of bleeding in the perioperative setting.

Descriptif du produit:

Visual Identification: Clear solution; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 3 Years; Container Temperature: Store between 2 - 25 degrees celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Registered

Date de l'autorisation:

2020-11-19